XERIS BIOPHARMA HOLDINGS, INC. Interest Expense
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Interest Expense of $7.03 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement
us-gaap:InterestExpense · last filed 2024-05-09
- XERIS BIOPHARMA HOLDINGS, INC. interest expense for the quarter ending 2024-03-31 was $7.03M, a 13.13% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense for the quarter ending 2023-12-31 was $7.02M, a 60.71% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense for the quarter ending 2023-09-30 was $6.85M, a 71.65% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense for the quarter ending 2023-06-30 was $6.53M, a 89.33% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense for fiscal 2023 was $26.61M, a 88.69% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense for fiscal 2022 was $14.10M, a 96.41% increase from fiscal 2021.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense for fiscal 2021 was $7.18M, a 32.65% decline from fiscal 2020.
- XERIS BIOPHARMA HOLDINGS, INC. interest expense for fiscal 2020 was $10.66M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 9 month as first filed | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-03-31 | $7.03M 10-Q · filed 2024-05-09 | $14.05M derived: sum of 2 quarters · filed 2024-05-09 | $20.90M derived: sum of 3 quarters · filed 2024-05-09 | $27.43M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-12-31 | $7.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $13.87M derived: sum of 2 quarters · filed 2024-03-06 | $20.39M derived: sum of 3 quarters · filed 2024-03-06 | $26.61M 10-K · filed 2024-03-06 | ||
| 2023-09-30 | $6.85M 10-Q · filed 2023-11-09 | $13.38M derived: sum of 2 quarters · filed 2023-11-09 | $19.59M 10-Q · filed 2023-11-09 | $23.96M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-06-30 | $6.53M 10-Q · filed 2023-08-08 | $12.74M 10-Q · filed 2023-08-08 | $17.11M derived: sum of 3 quarters · filed 2024-05-09 | $21.10M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2023-03-31 | $6.22M 10-Q · filed 2024-05-09 | $10.58M derived: sum of 2 quarters · filed 2024-05-09 | $14.57M derived: sum of 3 quarters · filed 2024-05-09 | $18.02M derived: sum of 4 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $4.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $8.36M derived: sum of 2 quarters · filed 2024-03-06 | $11.80M derived: sum of 3 quarters · filed 2024-03-06 | $14.10M 10-K · filed 2024-03-06 | $15.32M 10-K · filed 2023-03-08 | |
| 2022-09-30 | $3.99M 10-Q · filed 2023-11-09 | $7.44M derived: sum of 2 quarters · filed 2023-11-09 | $9.73M 10-Q · filed 2023-11-09 | $10.96M 10-Q · filed 2022-11-09 | $12.75M derived: sum of 4 quarters · filed 2024-03-06 | |
| 2022-06-30 | $3.45M 10-Q · filed 2023-08-08 | $6.97M 10-Q · filed 2023-08-08 | $8.77M derived: sum of 3 quarters · filed 2024-03-06 | $10.56M derived: sum of 4 quarters · filed 2024-03-06 | ||
| 2022-03-31 | $3.52M 10-Q · filed 2023-05-09 | $5.32M derived: sum of 2 quarters · filed 2024-03-06 | $7.12M derived: sum of 3 quarters · filed 2024-03-06 | $8.91M derived: sum of 4 quarters · filed 2024-03-06 | ||
| 2021-12-31 | $1.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $3.59M derived: sum of 2 quarters · filed 2024-03-06 | $5.39M derived: sum of 3 quarters · filed 2024-03-06 | $7.18M 10-K · filed 2024-03-06 | ||
| 2021-09-30 | $1.80M 10-Q · filed 2022-11-09 | $3.59M derived: sum of 2 quarters · filed 2022-11-09 | $5.38M 10-Q · filed 2022-11-09 | $9.97M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $1.79M 10-Q · filed 2022-08-10 | $3.59M 10-Q · filed 2022-08-10 | $8.18M derived: sum of 3 quarters · filed 2022-08-10 | $10.51M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | $1.79M 10-Q · filed 2022-05-11 | $6.38M derived: sum of 2 quarters · filed 2022-05-11 | $8.71M derived: sum of 3 quarters · filed 2022-05-11 | |||
| 2020-12-31 | $4.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $6.92M derived: sum of 2 quarters · filed 2022-03-11 | $10.66M 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $2.33M 10-Q · filed 2021-11-10 | $6.07M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |